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Protein kinase-like domains that lack conserved residues known to catalyse phosphoryl transfer, 
termed pseudokinases, have emerged as important signalling domains across all kingdoms of life. 
Although predicted to function principally as catalysis-independent protein-interaction modules, 
several pseudokinase domains have been attributed unexpected catalytic functions, often amid 
controversy. We established a thermal-shift assay as a benchmark technique to define the 
nucleotide-binding properties of kinase-like domains. Unlike in vitro kinase assays, this assay is 
insensitive to the presence of minor quantities of contaminating kinases that may otherwise lead to 
incorrect attribution of catalytic functions to pseudokinases. We demonstrated the utility of this 
method by classifying 31 diverse pseudokinase domains into four groups: devoid of detectable 
nucleotide or cation binding; cation-independent nucleotide binding; cation binding; and 
nucleotide binding enhanced by cations. Whereas nine pseudokinases bound ATP in a divalent 
cation-dependent manner, over half of those examined did not detectably bind nucleotides, 
illustrating that pseudokinase domains predominantly function as non-catalytic protein-interaction 
modules within signalling networks and that only a small subset is potentially catalytically active. 
We propose that henceforth the thermal-shift assay be adopted as the standard technique for 
establishing the nucleotide-binding and catalytic potential of kinase-like domains.
Keywords
nucleotide binding; non-catalytic protein-interaction domain; protein kinase; pseudoenzyme; 
pseudokinase
INTRODUCTION
Although first described in sea urchins [1], examples of pseudokinase domains are now 
known across all kingdoms of life. In previous years, essential functions in signal 
transduction have been attributed to these protein kinase-like domains, principally as 
modulators of the catalytic activities of bona fide protein kinases or as scaffolding proteins 
that nucleate the assembly of signalling complexes [2–14]. Often amid controversy, several 
pseudokinase domains have been reported to exhibit a low catalytic activity, yet the 
importance of this enzymatic activity to the protein’s biological function and the ubiquity of 
this phenomenon across all pseudokinases remain unclear.
Pseudokinase domains were originally predicted to be devoid of any catalytic activity owing 
to the absence of one or more of the three crucial residues known to catalyse phosphoryl 
transfer in active protein kinases (Figure 1A). These residues are located within highly 
conserved motifs: (i) the VAIK motif, where the lysine residue in the β3 strand of the N-lobe 
positions the ATP α- and β-phosphates for catalysis; (ii) the HRD motif in the catalytic loop, 
which crucially contributes the catalytic aspartic acid residue; and (iii) the DFG motif within 
the activation loop contributes an aspartic acid residue involved in binding Mg2+ that 
stabilizes the bound ATP [15,16]. More recently, further consideration has been given to the 
integrity of the [GSA]xGxx[GSA] motif (where x is any amino acid) in the glycine-rich loop 
(‘G-loop’ or ‘P-loop’) that connects the β1 and β2 strands of the kinase domain N-lobe, 
since the flexibility of this loop is a key factor in promoting ATP binding [17]. Despite the 
absence of one or more of the three canonical catalytic residues, previous studies have 
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reported nucleotide binding and enzymatic activities for a number of pseudokinases [14,18–
21], raising the prospect that it might be a more general phenomenon of pseudokinases.
A prerequisite underlying whether a pseudokinase might exhibit catalytic activity is to 
define whether it binds to nucleotides in the presence of divalent cations. Having extensively 
reviewed the methods available to characterize the nucleotide-binding properties of 
pseudokinases [22], we used the most robust technique, the thermal-shift assay, to examine 
nucleotide and divalent cation binding by pseudokinase domains in vitro. This assay 
obviates the need for specific fluorescently tagged nucleotides, such as TNP-ATP [2(3)-O-
(2,4,6-trinitrophenyl) adenosine 5-triphosphate], which have been reported to bind targets 
with affinities several hundred-fold greater than ATP in some cases [23] or non-specifically 
fluoresce in the presence of BSA (P.A. Eyers and D. Ungureanu, unpublished work). 
Additionally, the assay monitors the thermal denaturation of the major protein species, so 
any minor contaminants, including co-purified protein kinases, that would lead to 
misleading results in radiometric in vitro kinase assays do not contribute to the signal. Using 
this assay, we experimentally defined the nucleotide- and divalent cation-binding properties 
of a collection of 31 diverse pseudokinase domains, including almost half of the human 
pseudokinome, and found that the majority of examined pseudokinases did not detectably 
bind nucleotides. The findings of the present study are consistent with the idea that these 
domains predominantly serve non-enzymatic functions in cellular signalling networks.
EXPERIMENTAL
Recombinant protein expression and purification
The sources of cDNA templates used in the preparation of the expression constructs are 
shown in Supplementary Table S1 (at http://www.biochemj.org/bj/457/bj4570323add.htm). 
Insect cell expression was performed using Sf21 cells [except for JAK1(JH2) (where JAK is 
Janus kinase and JH2 is JAK homology 1), TYK2(JH2) (where TYK2 is tyrosine kinase 2) 
and HER3 (human epidermal growth factor receptor 3)/ErbB3 (v-erb-b2 avian erythroblastic 
leukaemia viral oncogene homologue 3), which used Sf9 cells] as described previously [20] 
starting from the pFastBac HTb or pFastBac1 vectors (LifeTechnologies) or a pAceBac1-
derived vector (ATG Biosynthetics) to generate His6−tagged proteins. Bacterial expression 
constructs were prepared analogously to incorporate N-terminal His6 tags. VRK3 (vaccinia-
related kinase 3) and CRN (also known as CORYNE) were cloned into pProEX HTb 
(LifeTechnologies); SgK495 [sugen kinase 495; also known as STK40 (serine/threonine 
kinase 40)] and TRB2 [also known as TRIB2 (tribbles pseudokinase 2)] were cloned into 
pET30 Ek/LIC (Novagen); SgK223 and SgK269 [also known as PEAK1 (pseudopodium-
enriched atypical kinase 1)] were cloned into pCOLD IV (Clontech); and ROP2 (rhoptry 
protein kinase 2) and BPK1 (bradyzoite pseudokinase 1) were cloned into pET28a 
(Clontech), and expression was performed according to established protocols [24]. Typically, 
proteins were purified using a standardized procedure [20], before Superdex-200 gel-
filtration chromatography (GE Healthcare) in 200 mM NaCl, 20 mM Tris/HCl, 10% (v/v) 
glycerol and 0.5 mM TCEP [tris-(2-carboxyethyl)phosphine] (pH 8.0).
The expression and purification of JAK2(JH1) [25,26], ILK (integrin-linked kinase)–α-
parvin CH2 (calponin homology 2) domain complex [27], HER3/ErbB3 [4], MviN [28], 
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ROP5BI [29], JAK2(JH2) [20] and STRADα (STE20-related kinase adaptor α) [30] were 
performed as described in their respective references. Typically, proteins were concentrated 
to 2 mg/ml or higher, snapfrozen in liquid N2 and stored at −80◦C until required. Protein 
concentrations were estimated on the basis of absorbance at 280 nm and the calculated 
molar absorption coefficients.
Thermal-shift assay for nucleotide binding
Thermal-shift assays were performed using a Corbett Real Time PCR machine with proteins 
diluted in 150 mM NaCl, 20 mM Tris/HCl (pH 8.0) and 1 mM DTT to 2–5 μM and assayed 
with the appropriate concentration of ligand in a total reaction volume of 25 μl. SYPRO 
Orange (Molecular Probes) was used as a probe with fluorescence detected at 530 nm. The 
temperature was raised in 1◦C per min steps from 25◦C to 95◦C and fluorescence readings 
were taken at each interval. Nucleotide- or cation-binding experiments were assessed 
relative to a buffer control. Two generic inhibitors, DAP {N′2′-(4-aminomethyl-phenyl)-5-
fluoro-N′4′-phenyl-pyrimidine-2,4-diamine [31]; supplied by SYNthesis Med Chem} and 
VI16832 [32], were assessed relative to a 2% (v/v) DMSO control. With the exception of the 
titration experiments, nucleotide concentrations of 0.2 mM, divalent cation concentrations of 
1 mM, and DAP or VI16832 concentrations of 40 μM were used in each experiment. For 
each well, sample fluorescence was plotted as a function of increasing temperature. The 
melting temperature (Tm) corresponding to the midpoint for the protein unfolding transition 
was calculated by fitting the sigmoidal melt curve to the Boltzmann equation using 
GraphPad Prism, with R2 values of >0.99. Data points after the fluorescence intensity 
maximum were excluded from fitting. Changes in the unfolding transition temperature 
compared with the control curve (ΔTm) were calculated for each ligand (nucleotides 
cations). A positive ΔTm value indicates that the ligand stabilizes the protein from 
denaturation, and therefore binds the protein. A minimum of two independent assays was 
performed for each protein and representative data are shown for each.
ITC
ITC (isothermal titration calorimetry) was performed using a MicroCal instrument (GE 
Healthcare). ATP (0.5 mM with no added divalent cations) was titrated into a solution of 50 
μM human MLKL (mixed lineage kinase domain-like) pseudokinase domain at 25◦C. Both 
samples were prepared in 200 mM NaCl, 20 mM Hepes and 5% (v/v) glycerol (pH 7.5).
RESULTS
Selection and preparation of target pseudokinase domains
A diverse group of pseudokinase domains were selected for expression, purification and 
nucleotide-binding studies to represent a cross-section of domains lacking different 
combinations of catalytic residues from the VAIK, HRD and DFG motifs (Figure 1). We 
also examined the proteins Ror1 (receptor tyrosine kinase-like orphan receptor 1), BubR1 
[also known as BUB1B (BUB1 mitotic checkpoint serine/threonine kinase B)] and RYK 
(receptor-like tyrosine kinase), which despite containing the key residues of the VAIK, HRD 
and DFG motifs did not exhibit catalytic activity in earlier studies [33–36]. In addition to the 
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23 human and two mouse pseudokinases chosen for examination, we also analysed the 
bacterial pseudokinase MviN [28], two plant pseudokinases, CRN (CORYNE) [37] and 
TARK1 (tomato atypical receptor-like kinase 1) [38], and three Toxoplasma gondii 
pseudokinases, ROP5BI [29], ROP2 [39] and BPK1 [40].
In most cases, pseudokinases were overexpressed and purified from insect cells (Figures 1B 
and 1C). All were prepared either with a His6 tag or proteolytically cleaved to remove 
globular affinity tags, such as GST and MBP (maltose-binding protein), since these domains 
will themselves undergo denaturation in the thermal-shift assay and may obscure detection 
of ligand binding to pseudokinase domains. Because some pseudokinase domains are 
unstable in their apo forms, we sought to test whether the assay was amenable to examining 
ligand binding within protein complexes by examining ILK co-expressed and purified in 
complex with the CH2 domain of α-parvin [27,41]. Coomassie Blue-stained SDS/PAGE 
gels of the recombinant proteins examined in the present study are shown in Figure 1(B).
A thermal-shift assay for examining nucleotide and cation binding
Initially, we established an assay to evaluate nucleotide and cation binding to pseudokinase 
domains. The assay, based on an earlier method [42], monitors the thermal denaturation of a 
test protein by measuring the fluorescence arising from binding of the dye SYPRO Orange 
to hydrophobic patches that become exposed during denaturation. Ligand binding to a 
protein is known to enhance a protein’s thermal stability, which manifests in an elevated 
melting temperature (Tm) that can be used to measure ligand binding. Relative to many other 
methods that have previously been explored to characterize nucleotide binding to kinase-like 
domains [22], the thermal-shift assay offers the following advantages: (i) modest quantities 
of recombinant protein (2–5 μg per condition) can be used; (ii) an RT-PCR (real-time PCR) 
instrument, a common piece of laboratory equipment, can be used; (iii) depending upon the 
RT-PCR instrument, 96 or 384 conditions can be tested simultaneously; (iv) the binding of 
any ligand, even a simple divalent cation such as Mg2+, can be assessed without fluorescent 
tagging of the ligand; (v) the assay is extremely sensitive, being able to detect interactions 
with affinities in the 10−4 M range; and (vi) the presence of minor quantities of 
contaminating kinases will not affect the assay, since the denaturation measurement is 
dominated by the major species.
We validated our assay using human MLKL, whose mouse orthologue had already shown 
ATP binding in this assay [43]. We measured ATP binding to human MLKL by both 
thermal-shift assay and ITC, which yielded comparable Kd values (∼15 μM; Supplementary 
Figures S1A and S1B at http://www.biochemj.org/bj/457/bj4570323add.htm). These studies, 
coupled with those reported previously for other kinases [44], provide important validation 
that the magnitudes of the thermal shifts correlate with ligand-binding affinities and thus that 
the thermal-shift assay provides an accurate representation of ligand binding. To gauge the 
sensitivity of the assay, we examined whether the assay could detect ADP–Mg2+ binding to 
the active tyrosine kinase domain of JAK2 (the ‘JH1’ domain), a domain we have previously 
shown to bind ADP–Mg2+ with a Kd value of ∼100 μM [45]. As shown in Supplementary 
Figures S1(C) and S1(D), we could indeed detect binding of JAK2(JH1) to a variety of 
nucleotides in the presence of Mg2+, including ADP. On the basis of these preliminary 
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studies, we estimated that this assay can detect ligand binding down to sub-millimolar Kd 
values. Indeed, a recent study using an alternative technique demonstrated that EphB6 
(Ephrin type-B receptor 6) binds GTP–Mg2+ with a Kd value of >500 μM [46], and this 
interaction was also successfully detected in our assay (Figure 3C).
Classification of pseudokinases
We proceeded to qualitatively assess the propensity of each of 31 recombinant pseudokinase 
domains (Figure 1) to bind divalent cations (Mg2+ or Mn2+), nucleotides {AMP, ADP, ATP, 
AMP-PNP (adenosine 5′-[β,γ-imido]triphosphate) and GTP}or both cation and nucleotide 
together. We also examined binding to two promiscuous ATP-competitive inhibitors, DAP 
[31] and VI16832 [32] (structures shown in Supplementary Figures S1E and S1F), as a 
means of evaluating whether the proteins contained an accessible, potentially druggable, 
pocket equivalent to the nucleotide-binding site of a catalytically active kinase. On the basis 
of our experience using this technique to screen for small molecule kinase inhibitors, we 
deemed a ΔTm value of ⩾3◦C to be a robust indicator of ligand binding.
On the basis of their ligand-binding properties in the thermal-shift assay, we categorized the 
31 pseudokinases into four classes: (i) devoid of detectable nucleotide or cation binding; (ii) 
nucleotide binding; (iii) cation binding; and (iv) nucleotide and cation binding. As 
summarized in Table 1, more than half (16) of the pseudokinases did not detectably bind 
nucleotides or cations in our assay (Figure 2 and Supplementary Figure S2 at http://
www.biochemj.org/bj/457/bj4570323add.htm). Interestingly, although we did not detect 
nucleotide or cation binding for TYK2(JH2) and IRAK3 (interleukin-1-receptor-associated 
kinase 3) (Figures 2E and 2F), both proteins were capable of binding the inhibitors DAP and 
VI16832, indicating the presence of an intact ATP-binding cleft and raising the possibility 
that these domains may bind nucleotides at affinities below the sensitivity of the assay. As 
shown in Figure 3, four proteins bound nucleotide alone [MLKL, EphB6, STRADα and 
ULK4 (unc-51 like kinase 4); Class 2] and two bound cations alone (SgK269 and ROP2; 
Class 3). It should be noted that the thermal shifts observed for Class 3 pseudokinases in the 
presence of nucleotides and cations can be accounted for by the presence of Mn2+ alone 
(Figures 3F and 3G). Fewer than one-third of the pseudokinase domains tested (9 of 31) 
bound nucleotide and cation: JAK1(JH2), JAK2(JH2), ILK, HER3/ErbB3, SgK071, CRN, 
ROP5BI, IRAK2 and TARK1 (Figure 4 and Supplementary Figure S3 at http://
www.biochemj.org/bj/457/bj4570323add.htm). Of note, our assay was amenable to 
examining the nucleotide and cation binding of pseudokinases within complexes with other 
protein-interaction domains. We were able to assay ILK (Figure 4C and Supplementary 
Figure S3C), even though its stability relies on being in complex with the α-Parvin CH2 
domain.
RYK contains each of the three canonical residues present in active protein kinases, but is 
known to be catalytically inactive [36] and did not detectably bind nucleotides or cations in 
our assays. To test whether the highly conserved phenylalanine residue within the TFVK 
sequence, the counterpart of a conventional kinase’s VAIK motif, might occupy the adenine-
binding pocket and prevent nucleotide binding, we examined a TFVK>VAVK mutant RYK 
by thermal shift. Although this mutation did not result in detectable nucleotide binding, the 
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mutant was able to engage the promiscuous ATP-competitive inhibitor DAP, whereas wild-
type RYK did not (Figures 2B and 2C). ATP binding by a second protein, EphB6, was not 
enhanced by the presence of divalent cations (Figure 3C), leading us to query whether the 
R813LG sequence in place of the canonical DFG motif might serve a role in binding the γ-
phosphate of ATP, effectively supplanting the conventional Mg2+ . Introduction of the 
R813D mutation abrogated the direct binding of ATP by EphB6 in the absence of cations, 
but conferred an unexpected ability to bind ATP in the presence of Mn2+ (Figure 3D).
It is surprising that BubR1, which contains the catalytic residues typical of an active protein 
kinase, did not bind nucleotides in the presence or absence of divalent cations (Figure 2A). 
To ensure that this was not a consequence of the domain boundaries (residues 724–1043) we 
used initially, we also characterized a longer construct (residues 720–1043), similar to that 
used in [35], which contains the kinase extension domain that is critical for catalytic activity 
of the related bona fide protein kinase BUB1 [47]. We expressed BubR1 in both Sf21 and 
Escherichia coli cells and found that all preparations behaved equivalently in the thermal-
shift assay (results not shown), confirming the inability of BubR1 to detectably bind to 
nucleotides or divalent cations.
DISCUSSION
The importance of pseudokinases to cellular signalling has only recently begun to be 
appreciated. Fuelled by the discovery that mutations within the pseudokinase domain of 
JAK2 underlie human blood cell malignancies [48–52], pseudokinases have emerged as an 
unexplored family of therapeutic targets. Previous studies have attributed unexpected 
catalytic functions to several pseudokinase domains, including that of JAK2 [20], ErbB3 
[19] and KSR2 (kinase suppressor of Ras 2) [14], although whether nucleotide-binding and, 
relatedly, phosphoryl transfer activity is a widespread property within this domain family 
has remained unclear. We have addressed this issue by profiling the nucleotide-binding 
properties of a collection of 31 diverse pseudokinase domains using a robust thermal-shift 
assay.
Thermal-shift assay data are supported by prior structural studies
Although we have performed a comprehensive examination of ATP, ADP, AMP, AMP-PNP 
and GTP binding in the presence or absence of Mg2+ or Mn2+ in the present study, structural 
and biophysical studies have previously explored the ATP-binding capacities of some 
pseudokinases included in the present study [4,17–19,22,27–30,39,41,53,54]. With the 
exception of CASK (calcium/calmodulin-dependent serine protein kinase), all of these prior 
findings are supported by the present study, providing a sound foundation for the results 
reported in the present paper for formerly uncharacterized pseudokinases. The absence of 
ATP binding to CASK using the thermal-shift assay is unsurprising (Figure 2D), since our 
interpretation of the prior CASK ATP-binding data [18] suggests a Kd(ATP) value in the 
millimolar range, an affinity beyond the range of detection using most biophysical 
techniques. Accordingly, we were unable to detect nucleotide binding to CASK prepared 
from E. coli (results not shown) or insect cells (Figure 2D). The structure of the TYK2(JH2) 
domain bound to an ATP-mimetic inhibitor was recently solved (PDB code 3ZON), 
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confirming the presence of an accessible active site: a finding consistent with the binding to 
the small-molecule kinase inhibitors DAP and VI16832 observed in the present study 
(Figure 2E). Although the structure of the Ror1 pseudokinase domain has not yet been 
solved, an absence of ATP binding in the present study can be rationalized by inspection of 
the structures of the related Ror2 (PDB codes 3ZZW and 4GT4) [55], where the adenine-
binding pocket is partly occupied by the side chain of the highly conserved Tyr555.
Pseudokinases function principally as catalysis-independent protein-interaction modules
The largest class of pseudokinases observed in the present study did not detectably bind 
nucleotides or divalent cations (Class 1; Figure 2 and Table 1, and Supplementary Figure 
S2), providing compelling support for the hypothesis that pseudokinase domains serve 
predominantly non-catalytic functions within signalling networks in Nature. Of these, Ror1 
[33,34], RYK [36], CCK4 (colon carcinoma kinase 4)/PTK7 (protein tyrosine kinase 7) [56], 
BubR1 [35], IRAK3/IRAK-M [57] and MviN [28] were not catalytically active in vitro in 
previously published studies, consistent with our observations that they do not bind ATP.
Nucleotide-binding (Class 2) pseudokinases
Prior studies of the nucleotide-binding-only proteins STRADα and EphB6 did not reveal 
kinase activity in vitro [30,58,59], in keeping with our premise that both ATP and cation 
binding are necessary for catalytic activity. Human MLKL has previously been attributed a 
catalytic function based on in vitro kinase assays with protein immunoprecipitated from 
HEK (human embryonic kidney)-293T cells [60]. However, on the basis of our previous 
characterization of mouse MLKL [43], and the analogous cation-independent nucleotide-
binding properties observed for human MLKL in the present study, it is probable that the 
catalytic activity previously attributed to MLKL is likely to arise from the catalytic activity 
of a contaminating protein. A fourth protein, ULK4, has not been characterized 
biochemically, though cation-independent nucleotide binding indicates that ULK4 will 
similarly serve non-catalytic signalling roles.
A common feature of STRADα, MLKL, EphB6 and ULK4 is divergent sequences in place 
of the conventional cation-binding DFG motif. In the case of STRADα and EphB6, the DFG 
motif is replaced by GLR and RLG respectively. Since the GLR sequence was shown to play 
a key role in mediating ATP binding by STRADα [30], we examined whether the R813LG 
counterpart in EphB6 might play a similar role. R813D mutant EphB6 exhibited a 
predictable loss of nucleotide binding in the absence of divalent cations in the thermal-shift 
assay, but an unexpected gain of Mn2+ -dependent ATP binding (Figure 3D). This finding is 
intriguing, since the RLG>DLG mutation confers nucleotide-binding properties on EphB6 
that are synonymous with a conventional protein kinase, although in the absence of a 
catalytic residue in the catalytic loop, we anticipate that R813D EphB6 will not be 
enzymatically active. An examination of orthologous sequences revealed that the arginine 
residue of the RLG motif is conserved almost universally as one of two basic residues 
(arginine or histidine) in mammalian EphB6 orthologues, whereas other orthologues, 
including those in fish (including lamprey), chicken, zebra finch and turkey, contain a DFG 
sequence in addition to intact VAIK (or VAVK) and HRD motifs. These observations 
indicate that mammalian EphB6 orthologues evolved from a catalytically active ancestral 
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protein kinase to serve non-catalytic nucleotide-binding functions in cell signalling, 
presumably as means of modulating protein conformation. Remarkably, the evolution of the 
RLG sequence in place of the canonical DFG motif has coevolved with substitutions within 
the VAIK and HRD motifs. Our findings demonstrate an important role for the RLG 
sequence in facilitating nucleotide binding in mammalian EphB6 orthologues that is likely 
to have evolved to compensate for the concomitant substitution of the VAIK motif to VAIQ. 
The existence of the Class 2 pseudokinases provides important support for the emerging idea 
that nucleotide binding among pseudokinases may have evolved as a non-catalytic 
conformational switch, as proposed for STRADα [30,54] and MLKL [43]. An exciting 
possibility is that conformational regulation by nucleotide binding, rather than catalytic 
functions, may similarly underlie the functions of Class 4 pseudokinases as protein-
interaction modules within signalling networks.
The Class 2 pseudokinases also offer important mechanistic insights into the contributions of 
the VAIK motif lysine residue to ATP binding in both pseudokinases and catalytically active 
kinases. Consistent with a prior study of the bona fide protein kinase Lck (lymphocyte-
specific protein tyrosine kinase) [61], where the VAIK motif lysine residue was shown to 
serve a catalytic rather than ATP-binding function, we observed that ATP binding was still 
accomplished by EphB6 and ULK4 (Figures 3C and 3E), two pseudokinases containing 
VAIQ and VAIL respectively in place of the canonical VAIK motif. In some pseudokinase 
domains, however, it appears that the VAIK motif lysine residue has evolved an essential 
role in ATP binding, as illustrated by mutational analyses of mouse [43] and human [62] 
MLKL, both Class 2 pseudokinases, and HSER (heat-stable enterotoxin receptor)/GC-C 
(guanylate cyclase C) [63]. As a result, it appears that in the absence of other key ATP- 
and/or divalent cation-binding residues, some pseudokinases have evolved a greater reliance 
on the VAIK motif lysine residue to mediate ATP binding. Furthermore, these findings raise 
the intriguing possibility that the VAIK motif lysine residue may mediate ATP binding, 
rather than have a catalytic function, in a subset of catalytically active protein kinases.
Cation-binding (Class 3) pseudokinases
Pseudokinases that bound divalent cations alone include SgK269/PEAK1 and the T. gondii 
protein ROP2 (Figures 3F and 3G and Table 1). Consistent with the original study of ROP2 
[39], we observed no ATP binding in our assays although, curiously, we did detect GTP 
binding in a cation-independent manner. This observation is most consistent with ROP2 
containing an intact nucleotide-binding pocket that allows ROP2 to retain either a Mn2+ - or 
GTP-binding capacity, albeit in the absence of catalytic activity. By comparison, SgK269 
had previously been attributed a catalytic activity [64,65], although in our hands it did not 
detectably bind ATP: a finding more consistent with the highly degraded G-loop and the 
absence of the conserved aspartic acid residue in the DFG motif. Interestingly, SgK223, a 
protein closely related to SgK269, likewise did not bind nucleotides in our assays, but, in 
contrast with SgK269, did not bind Mn2+ ions (Supplementary Figure S2B). It should be 
noted that the bacterial pseudokinase MviN showed evidence of Mn2+ binding, but because 
the ΔTm value in the presence of Mn2+ was <3◦C, it did not meet our criteria to be 
categorized as cation binding (Figure 2G).
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Nucleotide- and cation-binding (Class 4) pseudokinases
The prevalence of Class 1 pseudokinases and the identification of Classes 2 and 3 
demonstrate that the catalytic activity attributed to a subset of pseudokinase domains is not a 
widespread feature. We deemed nine of the 31 pseudokinases examined in the present study 
to be potentially catalytically active on the basis of the premise that both nucleotide and 
cation must be bound simultaneously for efficient phosphoryl transfer. Of these Class 4 
pseudokinases (Figure 4), catalytic activities have been reported for purified recombinant 
JAK2(JH2) [20] and ErbB3/HER3 [19], indicating that in some pseudokinases asparagine 
residues can substitute (albeit poorly) for the catalytic aspartic acid of the canonical HRD 
motif. IRAK2 immunoprecipitated from macrophages was previously attributed a catalytic 
function [66], although this has been recently queried [67]. In addition, on the basis of our 
JAK2(JH2) data, we anticipated that the related proteins, JAK1(JH2) and TYK2(JH2), 
would behave similarly to JAK2(JH2). Unexpectedly, we observed that TYK2(JH2) 
exhibited only modest, albeit consistent, thermal shifts in the presence of ATP–Mg2+, ATP–
Mn2+ or GTP–Mg2+ (Figure 2E), indicating that TYK2(JH2) may bind nucleotides in a 
cation-dependent manner, but with affinities below the sensitivity of our assay. In contrast, 
recent comprehensive structure/function studies have demonstrated that the pseudokinase 
domain of ILK is completely devoid of catalytic activity owing to a severely degraded 
catalytic core, and catalysis-independent functions have been elegantly established using 
knockin studies of ILK kinase-dead mutants in mice [68]. In addition, CRN, ROP5BI and 
TARK1 did not exhibit catalytic activity in published studies [29,37,38], supporting the idea 
that nucleotide binding by pseudokinase domains predominantly serves a role in modulating 
protein conformation, rather than catalytic functions, in cell signalling.
Can nucleotide-binding properties be predicted from pseudokinase amino acid 
sequences?
Although the nucleotide- and cation-binding (Class 4) pseudokinases constitute less than 
one-third of those profiled in the present paper, these domains were considered the most 
likely to be catalytically active and, as a result, we discuss some trends among this group 
that might aid their prediction in the future. First, combined G-loop degradation and the loss 
of the VAIK, DFG and HRD motifs thwarts nucleotide and cation binding and, accordingly, 
such sequence divergence is predictive of a catalytically inactive pseudokinase domain. 
Secondly, the DFG motif aspartic acid residue is present in nearly all pseudokinases that 
bind VI16832, DAP or nucleotide and cation (Table 1). Finally, among pseudokinase 
domains that bind nucleotide and cation (Class 4), the VAIK motif lysine residue (or, in 
some cases, arginine, such as in KSR2 [14]) and the DFG motif aspartic acid [or, in some 
cases, glutamic acid, such as in TARK1 (the present study)] are almost entirely conserved, 
with loss of only the catalytic aspartic acid from the HRD motif evident throughout Class 4. 
The sole loss of the catalytic aspartic acid residue in the HRD motif is not deleterious to 
nucleotide binding, since this catalytic residue is typically peripheral to the bound nucleotide 
and divalent cation in conventional protein kinases. Although not essential for nucleotide 
and cation engagement, the loss of the catalytic aspartic acid residue from the HRD motifs 
in the Class 4 pseudokinases is likely to severely limit their capacity to catalyse the 
phosphoryl transfer reaction. However, as noted previously [69], it remains unclear at this 
point how much catalytic activity is required in vivo for pseudokinases to play a significant 
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role in modulating signal transduction and, as discussed above, whether ATP binding might 
principally serve as a conformational switch that governs the capacities of pseudokinases to 
serve as protein-interaction domains.
Another trend that we observed is that, in general, Class 4 pseudokinases were less 
thermostable than Class 1. Although the Tm values of Class 1 pseudokinases were typically 
>40◦C, with Tm>50◦C observed for PTK7, BPK1, NRBP1 (nuclear receptor-binding protein 
1) and CASK, Class 4 proteins typically exhibited lower Tm values (<40◦C), suggesting a 
high degree of flexibility between the N- and C-lobes corresponding to a more ‘open’ ATP-
binding cleft in the absence of ligand. Exceptions to this generalization, such as the high 
thermal stability of the Class 4 protein ROP5BI (Supplementary Figure S3G), prevent 
thermal stability itself serving diagnostically as an indicator of the nucleotide-binding 
propensity. Nonetheless these data raise the interesting possibility that, for Class 2 and 4 
pseudokinases, the significant stabilization induced by ATP binding may be central to their 
ability to act as conformational switches or rigid scaffolds for intermolecular interactions.
Although a comprehensive understanding of this important family of domains awaits further 
biochemical, structural and biological characterization, the methodology and data of the 
present study provide a foundation for identifying pseudokinase domains that have retained 
a functional nucleotide-binding pocket. This subset of pseudokinase domains, including 
those known to be mutated in human cancers, such as JAK2(JH2) and HER3/ErbB3, are 
potentially druggable by ATP-competitive small molecules that could either inhibit weak 
catalytic activities or modulate the conformations of pseudokinases that serve as molecular 
switches in signalling pathways [30,43,54]. Consequently, these pseudokinases represent an 
exciting emergent class of drug targets. To this end, in future, we envisage that the 
methodology described in the present study will be utilized to screen for small-molecule 
lead compounds from which specific therapeutic modulators of pseudokinase functions 
could be developed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank Professor Dario Alessi (University of Dundee, Dundee, U.K.) for providing the GST–STRADα 
expression construct; Professor Seung-Taek Lee (Yonsei University, Seoul, Korea) for the PTK7/CCK4 template 
DNA; Dr Alessandra Gentile (Institute for Cancer Research and Treatment, Candiolo, Italy) for the Ror1 template 
cDNA; Dr Elton Zeqiraj (Tanenbaum-Lunenfeld Research Institute, Toronto, Canada) for assistance with the 
secondary-structure cartoon in Figure 1(C); and the Monash University Protein Production Unit for access to the 
Corbett RT-PCR instrument used for all of the thermal-shift assays.
FUNDING
This work was supported by the National Health and Medical Research Council (NHMRC) [grant numbers 637342 
and 1011804]; the Australian Research Council (ARC) [fellowships FT100100100 and FT110100169 (to J.M.M. 
and J.J.B.)]; the Leukaemia Foundation and the Australian Stem Cell Centre via scholarships to L.N.V.; the 
National Institutes of Health (NIH) [grant numbers R01 HL58758 (to J.Q.) and AI73756 (to M.L.R.)]; the Medical 
Research Council of Academy of Finland, the Sigrid Juselius Foundation, the Medical Research Fund of Tampere 
University Hospital, the Finnish Cancer Foundation and the Tampere Tuberculosis Foundation (to O.S.); the 
American Heart Association [grant number 11BGIA7440051 (to N.J.)]; and the National Science Foundation [grant 
number IOS-0821801 (to M.B.M.)]; with additional support from the Victorian State Government Operational 
Murphy et al. Page 11
Biochem J. Author manuscript; available in PMC 2017 November 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Infrastructure Support and the NHMRC Independent Research Institutes Infrastructure Support Scheme (IRIISS) 
[grant number 361646].
Abbreviations
AMP-PNP adenosine 5′-[β,γ-imido]triphosphate
BPK1 bradyzoite pseudokinase 1
CASK calcium/calmodulin-dependent serine protein kinase
CCK4 colon carcinoma kinase 4
CH2 calponin homology 2
CRN CORYNE
DAP N′2′ -(4-aminomethyl-phenyl)-5-fluoro-N′4′ -phenyl-pyrimidine-2,4-
diamine
EphB6 Ephrin type-B receptor 6
ErbB3 v-erb-b2 avian erythroblastic leukaemia viral oncogene homologue 3
HER3 human epidermal growth factor receptor 3
ILK integrin-linked kinase
IRAK interleukin-1-receptor-associated kinase
ITC isothermal titration calorimetry
JAK Janus kinase
JH JAK homology
KSR2 kinase suppressor of Ras 2
MLKL mixed lineage kinase domain-like
NRBP1 nuclear receptor-binding protein 1
PEAK1 pseudopodium-enriched atypical kinase 1
PTK7 protein tyrosine kinase 7
ROP rhoptry protein kinase
Ror1 receptor tyrosine kinase-like orphan receptor
RT-PCR real-time PCR
RYK receptor-like tyrosine kinase
SgK sugen kinase
STRADα STE20-related kinase adaptor α
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TARK1 tomato atypical receptor-like kinase 1
TRB2 tribbles pseudokinase 2
TYK2 tyrosine kinase 2
ULK4 unc-51 like kinase 4
VRK3 vaccinia-related kinase 3
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Figure 1. Pseudokinase domains selected for characterization of nucleotide binding
(A) Schematic cartoon of the eukaryotic protein kinase domain illustrating the amino acid 
motifs thought to be required for phosphoryl transfer that are usually absent from 
pseudokinase domains (depicted in the same style as [71]). (B) Purified pseudokinase 
domains (∼1 μg) were resolved by reducing SDS/PAGE and then were Coomassie Blue-
stained. Molecular mass markers are indicated on the left-hand side. In each case, the 
predominant species present in the preparation is the pseudokinase domain. (C) Multiple 
sequence alignment of canonical catalytic motifs in PKA (protein kinase A), a model serine/
threonine protein kinase, and JAK2(JH1), a model tyrosine kinase, with the 31 pseudokinase 
domains examined in the present study. Consensus sequences of the catalytic motifs and the 
protein kinase secondary structure are depicted as described previously ([72] and [73]). φ, 
hydrophobic; δ, hydrophilic; Φ, large hydrophobic; X, any amino acid. Subdomains are 
labelled according to the nomenclature proposed in [15]. The G-loop and the VAIK, HRD 
and DFG motifs of catalytically active protein kinases and their pseudokinase counterparts 
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are boxed in red, and residues thought to be essential for robust catalytic activity are shaded 
in green. Details of the species of origin, domain boundaries and expression strategy are 
given for each protein studied, with further details presented in the Experimental section and 
Supplementary Table S1 (at http://www.biochemj.org/bj/457/bj4570323add.htm). It should 
be noted that equivalent results were obtained for BubR1 with the domain boundaries of 
residues 720–1043 (results not shown).
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Figure 2. Thermal denaturation curves for selected Class 1 (non-binding) pseudokinase domains
Thermal denaturation curves of the Class 1 pseudokinases, BubR1 (A), wild-type RYK (B), 
CASK (D) and MviN (G) (upper panels) with the corresponding histograms depicting the 
ΔTm values in each condition (lower panels), as derived from analysis of upper panel curves. 
Although thermal denaturation of TFVK>VAVK RYK (C) and IRAK3 (F) was not affected 
by nucleotides or cations, TYK2(JH2) (E) exhibited modest, but consistent, thermal shifts 
between experiments in the presence of ATP–Mg2+, ATP–Mn2+ or GTP–Mg2+ . Thermal 
shifts for all three of these proteins were detected in the presence of the inhibitor VI16832 
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and/or DAP. A colour key for the curve labelling is to the right-hand side of the curves. In 
the histograms, bars are coloured according to the colour key when ΔTm>3◦C and pale blue 
otherwise. Thermal denaturation curves for the other Class 1 pseudokinases, Ror1, PTK7/
CCK4, SgK223, SgK495, TRB2, GCN2 [also known as EIF2AK4 (eukaryotic translation 
initiation factor 2-α kinase 4)], VRK3, BPK1, NRBP1 and SCYL1 (SCY1-like 1), are 
shown in Supplementary Figure S2 (at http://www.biochemj.org/bj/457/bj4570323add.htm).
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Figure 3. Thermal denaturation curves and ΔTm analyses of Class 2 (nucleotide binding) and 
Class 3 (cation binding) pseudokinases
Thermal denaturation data of the Class 2 pseudokinases, MLKL (A), STRADα (B), wild-
type EphB6 (C) and ULK4 (E), presented as described in the legend to Figure 2. (D) The 
R813D mutation converts EphB6 from a Class 2 into Class 4 pseudokinase. Note that wild-
type EphB6 (C) and ULK4 (E) are classified as Class 2 (nucleotide-binding) as the presence 
of Mn2+ and Mg2+ does not enhance ATP binding. Data for the Class 3 (cation-binding) 
pseudokinases ROP2 and SgK269 are presented in (F) and (G) respectively. Note that ROP2 
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and SgK269 are classified as Class 3 (cation-binding) pseudokinases because the presence of 
nucleotides does not confer further thermal stability above and beyond that of cation alone.
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Figure 4. ΔTm analyses of Class 4 (nucleotide- and cation-binding) pseudokinases
Histograms depicting the ΔTm value in each condition derived from thermal denaturation 
curves presented in Supplementary Figure S3 (at http://www.biochemj.org/bj/457/
bj4570323add.htm) for JAK1(JH2) (A), JAK2(JH2) (B), ILK (C), HER3/ErbB3 (D), 
SgK071 (E), CRN (F), ROP5BI (G), IRAK2 (H) and TARK1 (I). Note that some conditions 
are destabilizing, leading to negative ΔTm values. TARK1 (I) was categorized as Class 4 
owing to the observation of ATP–Mg2+, ADP–Mg2+, AMP-PNP–Mg2+ and GTP–Mg2+ 
binding. Interestingly TARK1 also appears to bind Mn2+ in the absence of nucleotides, 
leading to thermal-stability shifts under all Mn2+ -containing conditions.
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